Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
Identifieur interne : 001695 ( Main/Exploration ); précédent : 001694; suivant : 001696Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
Auteurs : Nikolina Basic-Jukic [Croatie]Source :
- Medical hypotheses [ 1532-2777 ] ; 2020.
Descripteurs français
- KwdFr :
- Humains (MeSH), Immunisation passive (méthodes), Immunoglobulines (composition chimique), Immunoglobulines par voie veineuse (usage thérapeutique), Immunosuppression thérapeutique (effets indésirables), Infections à cytomégalovirus (sang), Receveurs de transplantation (MeSH), Transplantation rénale (MeSH).
- MESH :
- composition chimique : Immunoglobulines.
- effets indésirables : Immunosuppression thérapeutique.
- méthodes : Immunisation passive.
- sang : Infections à cytomégalovirus.
- usage thérapeutique : Immunoglobulines par voie veineuse.
- Humains, Receveurs de transplantation, Transplantation rénale.
English descriptors
- KwdEn :
- COVID-19 (complications), COVID-19 (therapy), Cytomegalovirus Infections (blood), Humans (MeSH), Immunization, Passive (methods), Immunoglobulins (chemistry), Immunoglobulins, Intravenous (therapeutic use), Immunosuppression (adverse effects), Kidney Transplantation (MeSH), Transplant Recipients (MeSH).
- MESH :
- chemical , chemistry : Immunoglobulins.
- adverse effects : Immunosuppression.
- blood : Cytomegalovirus Infections.
- complications : COVID-19.
- methods : Immunization, Passive.
- chemical , therapeutic use : Immunoglobulins, Intravenous.
- therapy : COVID-19.
- Humans, Kidney Transplantation, Transplant Recipients.
Abstract
Information on treatment of COVID-19 infection in renal transplant recipients is scarce, especially in symptomatic patients and patients with recent major clinical events. This group of patients suffers from different opportunistic infections which may coexist with COVID-19. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Besides the immunosuppression reduction which is supposed to be beneficial, immunoglobulins with their immunomodulatory effects and possible antiviral role, may increase a possibility for favorable outcome.
DOI: 10.1016/j.mehy.2020.109903
PubMed: 32563969
PubMed Central: PMC7261461
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?</title><author><name sortKey="Basic Jukic, Nikolina" sort="Basic Jukic, Nikolina" uniqKey="Basic Jukic N" first="Nikolina" last="Basic-Jukic">Nikolina Basic-Jukic</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: nbasic@knc-zagreb.hr.</nlm:affiliation><country xml:lang="fr">Croatie</country><wicri:regionArea>Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb</wicri:regionArea><wicri:noRegion>Zagreb</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32563969</idno><idno type="pmid">32563969</idno><idno type="doi">10.1016/j.mehy.2020.109903</idno><idno type="pmc">PMC7261461</idno><idno type="wicri:Area/Main/Corpus">001352</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001352</idno><idno type="wicri:Area/Main/Curation">001352</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001352</idno><idno type="wicri:Area/Main/Exploration">001352</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?</title><author><name sortKey="Basic Jukic, Nikolina" sort="Basic Jukic, Nikolina" uniqKey="Basic Jukic N" first="Nikolina" last="Basic-Jukic">Nikolina Basic-Jukic</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: nbasic@knc-zagreb.hr.</nlm:affiliation><country xml:lang="fr">Croatie</country><wicri:regionArea>Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb</wicri:regionArea><wicri:noRegion>Zagreb</wicri:noRegion></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (complications)</term><term>COVID-19 (therapy)</term><term>Cytomegalovirus Infections (blood)</term><term>Humans (MeSH)</term><term>Immunization, Passive (methods)</term><term>Immunoglobulins (chemistry)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunosuppression (adverse effects)</term><term>Kidney Transplantation (MeSH)</term><term>Transplant Recipients (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains (MeSH)</term><term>Immunisation passive (méthodes)</term><term>Immunoglobulines (composition chimique)</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Immunosuppression thérapeutique (effets indésirables)</term><term>Infections à cytomégalovirus (sang)</term><term>Receveurs de transplantation (MeSH)</term><term>Transplantation rénale (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Immunoglobulins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunosuppression</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cytomegalovirus Infections</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Immunoglobulines</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunosuppression thérapeutique</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Passive</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Immunisation passive</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à cytomégalovirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunoglobulines par voie veineuse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Kidney Transplantation</term><term>Transplant Recipients</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Receveurs de transplantation</term><term>Transplantation rénale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Information on treatment of COVID-19 infection in renal transplant recipients is scarce, especially in symptomatic patients and patients with recent major clinical events. This group of patients suffers from different opportunistic infections which may coexist with COVID-19. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Besides the immunosuppression reduction which is supposed to be beneficial, immunoglobulins with their immunomodulatory effects and possible antiviral role, may increase a possibility for favorable outcome.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32563969</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?</ArticleTitle><Pagination><MedlinePgn>109903</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)30949-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.109903</ELocationID><Abstract><AbstractText>Information on treatment of COVID-19 infection in renal transplant recipients is scarce, especially in symptomatic patients and patients with recent major clinical events. This group of patients suffers from different opportunistic infections which may coexist with COVID-19. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Besides the immunosuppression reduction which is supposed to be beneficial, immunoglobulins with their immunomodulatory effects and possible antiviral role, may increase a possibility for favorable outcome.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Basic-Jukic</LastName><ForeName>Nikolina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: nbasic@knc-zagreb.hr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>129L90A25N</RegistryNumber><NameOfSubstance UI="C045781">cytomegalovirus-specific hyperimmune globulin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="N">Transplant Recipients</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hyperimmune anti-CMV globulin</Keyword><Keyword MajorTopicYN="N">Renal transplantation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32563969</ArticleId><ArticleId IdType="pii">S0306-9877(20)30949-X</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.109903</ArticleId><ArticleId IdType="pmc">PMC7261461</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):398-400</Citation><ArticleIdList><ArticleId IdType="pubmed">32113510</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Croatie</li></country></list><tree><country name="Croatie"><noRegion><name sortKey="Basic Jukic, Nikolina" sort="Basic Jukic, Nikolina" uniqKey="Basic Jukic N" first="Nikolina" last="Basic-Jukic">Nikolina Basic-Jukic</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32563969
|texte= Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32563969" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |